Tag Archives: HCoV-OC43

Huge underuse of germline testing for cancer patients

CHICAGO Fewer than 7 percent of newly diagnosed cancer patients are tested for germline gene mutations, and the percentage tested was even lower among racial and ethnic minorities, a huge study has found. Information from germline genetic testing could affect a patient’s cancer care. For example, such tests could indicate that targeted therapies would be… Read More »